• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease

Opinion
Video

Panelists discuss how hesitancy in prescribing amyloid-targeting therapies stems from multiple factors including concerns about ARIA adverse effects, modest clinical efficacy data, high treatment costs and limited insurance coverage, logistical challenges of regular infusions and monitoring, infrastructure requirements for specialized imaging, uncertainty about long-term benefits, and the need for careful patient selection within appropriate disease stages.

Video content above is prompted by the following:

  • What factors contribute to hesitancy in prescribing amyloid-targeting therapies?

Related Videos
1 expert in this video
Dr Gerard Criner
Dr Margrit Wiesendanger
4 experts are featured in this series.
4 experts are featured in this series.
2 experts in this video
2 experts in this video
Christine Funke, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.